

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **CLASP-7 TRANSMEMBRANE PROTEIN** the specification of which was filed on December 13, 2000 as Application No. 09/736,968.

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

**Prior Foreign Application(s)**

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/240,508	10/13/2000
60,240,503	10/13/2000
60/240,539	10/13/2000
60/240,543	10/13/2000
60/196,267	04/11/2000
60/196,527	04/11/2000
60/196,528	04/11/2000
60/196,460	04/11/2000
60,182,296	02/14/2000
60/176,195	01/14/2000
60/170,453	12/13/1999
60/162,498	10/29/1999
60/160,860	10/21/1999

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
09/547,276	04/11/2000	Pending




**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Andrew T. Serafini, Reg. No. 41,303  
 Hugh Wang, Reg. No. 47,163  
 William M. Smith, Reg. No. 30,223

Send Correspondence to: <b>Andrew T. Serafini, Ph.D.</b> <b>TOWNSEND and TOWNSEND and CREW LLP</b> <b>Two Embarcadero Center, 8<sup>th</sup> Floor</b> <b>San Francisco, California 94111-3834</b>	Direct Telephone Calls to: (Name, Reg. No., Telephone No.) Name: <b>Andrew T. Serafini, Ph.D.</b> Reg. No.: <b>41,303</b> Telephone: <b>650-326-2400</b>
--	--

Full Name of Inventor 1:	Last Name: <b>LU</b>	First Name: <b>PETER</b>	Middle Name or Initial: <b>S.</b>
Residence & Citizenship:	City: <b>Mountain View</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>99 East Middlefield Road 29</b>	City: <b>Mountain View</b>	State/Country: <b>California</b> Postal Code: <b>94043</b>
Full Name of Inventor 2:	Last Name: <b>GARMAN</b>	First Name: <b>JONATHAN</b>	Middle Name or Initial: <b>DAVID</b>
Residence & Citizenship:	City: <b>San Jose</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>5084 McCoy Avenue</b>	City: <b>San Jose</b>	State/Country: <b>California</b> Postal Code: <b>95130</b>
Full Name of Inventor 3:	Last Name: <b>CANDIA III</b>	First Name: <b>ALBERT</b>	Middle Name or Initial: <b>F</b>
Residence & Citizenship:	City: <b>Menlo Park</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>789 Marsh Road</b>	City: <b>Menlo Park</b>	State/Country: <b>California</b> Postal Code: <b>94025</b>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Peter S. Lu, M.D.	Signature of Inventor 2  Jonathan David Garman	Signature of Inventor 3  Albert F Candia III
Date <b>4/23/01</b>	Date <b>4/23/01</b>	Date <b>4/23/01</b>

SCANNED # 8

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
(37 CFR 1.9(f) & 1.27(c)) - SMALL BUSINESS CONCERNApplicant or Patentee:  
Application or Patent No.:  
Filed or Issued:  
Title:Peter S. Lu et al.  
09/736,968  
December 13, 2000  
CLASP-7 TRANSMEMBRANE PROTEIN

I hereby declare that I am:

- ☐ the owner of the small business concern identified below:  
☐ an official of the small business concern empowered to act on behalf of the concern identified below.

Name of Small Business Concern:  
Address of Small Business Concern:Arbor Vita Corporation  
772 Lucerne Drive  
Sunnyvale, CA 94085

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled CLASP-7 TRANSMEMBRANE PROTEIN by inventor(s) Peter S. Lu, Jonathan D. Garman, Albert F Candia III described in:

- ☐ the specification filed herewith;  
☒ Application No. 09/736,968, filed December 13, 2000;  
☐ Patent No. \_\_\_\_\_, issued \_\_\_\_\_.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name:  
Address:☐ Individual ☐ Small Business Concern ☐ Nonprofit OrganizationName:  
Address:☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing:  
Title of Person if Other than Owner:  
Address of Person Signing:Peter S. Lu  
Phar / CEO  
772 Lucerne Drive  
Sunnyvale, CA 94085

Signature

Date

4/23/01

ASSIGNMENT OF PATENT APPLICATION

JOINT

WHEREAS, Peter S. Lu, of 99 East Middlefield Road 29, Mountain View, CA 94043; Jonathan David Garman, of 5084 McCoy Avenue, San Jose, CA 95130; Albert F. Candia III, of 789 Marsh Road, Menlo Park, CA 94025; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: CLASP-7 TRANSMEMBRANE PROTEIN

**COPY**

Filing Date: December 13, 2000

Application No.: 09/736,968; and

WHEREAS, Arbor Vita Corporation, a corporation of the state of California, located at 772 Lucerne Drive, Sunnyvale, CA, 94085, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.


Assignors hereby authorize and request Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8<sup>th</sup> Floor, San Francisco, CA 94111-3834, to insert herein above the application number and filing date of said application when known.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: 4/23/01

  
Peter S. Lu

Dated: 4/23/01

  
Jonathan David Garman

Dated: 4/23/01

  
Albert F. Candia III

SCANNED # 8

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Peter S. Lu et al.Application No./Patent No.: 09/736,968Filed/Issue Date: December 13, 2000Entitled: CLASP-7 TRANSMEMBRANE PROTEINArbor Vita Corporation, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From:        To:       

The document was recorded in the United States Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

2. From:        To:       

The document was recorded in the United States Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

3. From:        To:       

The document was recorded in the United States Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

**(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]**

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

4/23/01

Date

Peter S. Lu

Signature

Peter S. Lu, M.D.

Typed or printed name

Pres / CEO

Title

**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.